Company
Merck KGaA
Merck KGaA has 18 drugs tracked on RxWires: 2 approved, 3 in Phase 3, 2 in Phase 2, 3 in Phase 1/2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| GONAL-F RFF REDI-JECT | Approved | |
| PERGONAL | Approved | |
| Enpatoran | Phase 3 | Systemic Lupus Erythematosus (SLE) |
| Avelumab | Phase 3 | Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
| Precemtabart tocentecan | Phase 3 | Metastatic Colorectal Cancer |
| MSB0010445 (0.3 milligram per kilogram [mg/kg]) | Phase 2 | Melanoma |
| COMPOUND 2055269 | Phase 2 | Locally Advanced Rectal Cancer |
| Cetuximab | Phase 1/2 | Glioblastoma Multiforme |
| M9140 | Phase 1/2 | Solid Tumors |
| Compound 451238 | Phase 1/2 | Soft-tissue Sarcoma |
| M7824 | Phase 1 | Cervical Cancer |
| M1774 | Phase 1 | Metastatic or Locally Advanced Unresectable Solid Tumors |
| M3554 | Phase 1 | Advanced Solid Tumor |
| M0324 | Phase 1 | Advanced Solid Tumor |
| M7437 | Phase 1 | Advanced Solid Tumors |
| M6620 | Phase 1 | Ovarian Cancer |
| M3814 100 mg | Phase 1 | Advanced Solid Tumors |
| Niaspan | Not Applicable | Atherosclerosis |
Latest
No recent events.
Follow Merck KGaA on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.